Search Within

Jason Earl Chan

  1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (15)
  2. Journal Article (10)
Groups
  1. Department of Medicine (25)
  2. Hematologic Malignancies, Division of (25)
  3. Sarcoma Service (25)
  4. Solid Tumor Oncology Division (25)
  5. Weinberg Fellows (22)
  6. GSK Faculty (21)

More Groups

People
  1. Ciara Kelly (21)
  2. Evan Rosenbaum (21)
  3. Mark Dickson (21)
  4. Mary Keohan (21)
  5. Ping Chi (21)
  6. Sandra D'Angelo (21)

More People

Years
  1. 2025 (1)
  2. 2024 (7)
  3. 2023 (4)
  4. 2022 (7)
  5. 2021 (2)
  6. 2020 (1)

More Years

Publications
  1. Journal of Clinical Oncology (8)
  2. Annals of Oncology (5)
  3. Clinical Cancer Research (4)
  4. Journal for ImmunoTherapy of Cancer (2)
  5. Nature Communications (2)
  6. Biology of Blood and Marrow Transplantation (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (8)
  2. Oxford University Press (6)
  3. American Association for Cancer Research (5)
  4. Nature Publishing Group (3)
  5. Biomed Central Ltd (2)
  6. Elsevier Inc. (1)

Results (25)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma
    Journal Article

    Movva, S.; Seier, K.; Bradic, M.; Charalambous, K.; Rosenbaum, E.; Kelly, C. M.; Cohen, S. M.; Hensley, M. L.; Avutu, V.; Banks, L. B.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas
    Meeting Abstract

    Rosenbaum, E.; Ehrich, F.; Bradic, M.; Kelly, C. M.; Movva, S.; Chan, J.; Chi, P.; Banks, L.; Dickson, M.; Keohan, M. L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A retrospective single-center study of outcomes to immune checkpoint blockade-based therapy in leiomyosarcoma
    Meeting Abstract

    Babatunde, O.; Rosenbaum, E.; Kelly, C. M.; Desir-Camille, R.; Keohan, M. L.; Banks, L.; Avutu, V.; Chan, J.; Reed, D.; Gounder, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naïve, advanced gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    Kelly, C. M.; Bradic, M.; Saunds, S.; Avutu, V.; Chan, J.; D'Angelo, S. P.; Dickson, M.; Gounder, M.; Keohan, M. L.; Movva, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma
    Meeting Abstract

    Rosenbaum, E.; Qin, L. X.; Dickson, M.; Movva, S.; Kelly, C. M.; Chan, J.; Chi, P.; Banks, L.; Keohan, M. L.; Gounder, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma
    Journal Article

    Movva, S.; Seier, K.; Avutu, V.; Banks, L. B.; Chan, J.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Do patients with myxofibrosarcoma and undifferentiated pleomorphic sarcoma have different clinical outcomes to immune checkpoint blockade-based therapy?
    Meeting Abstract

    Rosenbaum, E.; Seier, K.; Bradic, M.; Desir, R.; Kelly, C. M.; Movva, S.; Avutu, V.; Banks, L. B.; Chan, J. E.; Chi, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase I trial of CRD3874-SI, a systemically administered STING agonist, in patients with advanced solid tumors
    Meeting Abstract

    Kelly, C. M.; Avutu, V.; Banks, L. B.; Chan, J. E.; Chi, P.; Clark, C.; Counihan, O.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Immune-related adverse events after immune checkpoint blockade-based therapy are associated with improved survival in advanced sarcomas
    Journal Article

    Rosenbaum, E.; Seier, K.; Bradic, M.; Kelly, C.; Movva, S.; Nacev, B. A.; Gounder, M. M.; Keohan, M. L.; Avutu, V.; Chi, P.; more...
    Cancer Research Communications (2023)

    Fulltext@MSK | Save
  • A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma
    Meeting Abstract

    D'Angelo, S. P.; Rosenbaum, E.; Gularte Mérida, R.; Dickson, M. A.; Keohan, M. L.; Gounder, M. M.; Chi, P.; Movva, S.; Kelly, C. M.; Avutu, V.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save